New Tests Launched in October

By Alyssa Frank • November 9, 2017

Share this:

In October 2017, Mayo Medical Laboratories announced eight new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

New Tests

New tests launched in October 2017 by Mayo Medical Laboratories:

• CNS Demyelinating Disease Evaluation, Serum (ID: CDS1)
  Test Catalog | Overview PDF
• Dihydropyrimidine Dehydrogenase Genotype, Varies (ID: DPYDQ)
  Test Catalog | Overview PDF
• Focused Pharmacogenomics Panel, Varies (ID: PGXQP)
  Test Catalog | Overview PDF
• Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: MOGFS)
  Test Catalog | Overview PDF
• Neuromuscular Genetic Panels by Next-Generation Sequencing (NGS) (ID: NMPAN)
  Test Catalog | Overview PDF
• SERPINA1 Gene, Full Gene Analysis (ID: SERPZ)
  Test Catalog | Overview PDF
• Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping (ID: TPNUV)
  Test Catalog | Overview PDF
• Warfarin Response Genotype, Varies (ID: WARSQ)
  Test Catalog | Overview PDF

Test Updates

In addition to these new tests, the department also announced several test changes. Click the links below to view test changes announced via Mayo Medical Laboratories:

• All New Tests
• Test Changes Updates
• Test Status Updates
• View Full List

Alyssa Frank

Alyssa Frank is a Marketing Segment Manager at Mayo Clinic Laboratories. She leads marketing strategies for product management and specialty testing. Alyssa has worked at Mayo Clinic since 2015.